Joseph D. Zuckerman MD, FAAOS, Receives AAOS Highest Leadership Honor

The American Academy of Orthopahttps://www.aaos.org/edic Surgeons (AAOS) presented its 2021 William W. Tipton Jr., MD, Leadership Award to Joseph D. Zuckerman, MD, FAAOS.

The Tipton Leadership Award recognizes AAOS members who have demonstrated outstanding leadership qualities that have benefitted the orthopaedic community, patients, and/or the American public. The award honors and celebrates the life, accomplishments, and qualities of the late William W. Tipton Jr., MD, an orthopaedic surgeon, educator, and former AAOS chief executive officer.

“Bill was a special man who was always positive, constructive, and trying to push the agenda forward,” said Dr. Zuckerman. “To be recognized with this award by the AAOS, an organization I have so much respect and admiration for, is an honor.”

Similar to Dr. Tipton, Dr. Zuckerman’s life and career has been dedicated to helping grow the prestige of orthopaedic surgery nationally and internationally, according to Dr. Zuckerman’s colleague Kenneth A. Egol, MD, FAAOS, of NYU Langone Health.

“I cannot think of a better person to personify the qualities of a Tipton Leadership Award winner,” said Dr. Egol. “He is academically, administratively, clinically, and personally an exemplary leader in everything he does.”

Dr. Zuckerman is currently the chair of the Department of Orthopaedic Surgery at NYU Langone Health where he oversees a group of almost 200 orthopaedic surgeons and the day-to-day operations of programs that include orthopaedic surgery, rheumatology, and rehabilitation. Under Dr. Zuckerman’s stewardship, the department has achieved national prominence and received a top-10 ranking in National Institutes of Health funding for basic orthopaedic research.

“Under Dr. Zuckerman’s leadership our department has developed a professional curriculum for faculty and trainees that focuses on interpersonal communication skills, ethics, and an overarching commitment to patient safety,” said Dr. Egol.

Throughout his 30-year career as a practicing orthopaedic surgeon and teacher, Dr. Zuckerman has helped train and mentor hundreds of residents. He was named Teacher of the Year five times at NYU Langone Medical Center, has been awarded the Distinguished Teaching Medal from New York University, and the Master Educator Award from NYU School of Medicine.

“While Dr. Zuckerman is perhaps one of the most accomplished and influential orthopedic surgeons in the United States, his most impressive accomplishment, in my opinion, is how he’s utilized his platform to advance diversity and inclusion in the field of orthopedic surgery,” said Julius K. Oni, MD, FAAOS, of John Hopkins University School of Medicine, who studied under Dr. Zuckerman at NYU. “I don’t think there are enough words to truly express the impact he’s had on me and so many others.”

Dr. Zuckerman prioritized promoting diversity in the field of orthopaedics by implementing the use of the AAOS cultural competency training materials for faculty and trainees at NYU, and established a Diversity Committee within orthopaedic surgery, setting a precedent for other departments at NYU Langone Health. Dr. Zuckerman has also been a faculty champion to the NYU School of Medicine LGBT Society.

Dr. Zuckerman’s positive influence extends far beyond the walls of NYU. A past president of AAOS, Dr. Zuckerman served as chairman of the Council on Education for AAOS, and president of the American Shoulder and Elbow Surgeons (ASES).

Dr. Zuckerman has served as an ambassador of American orthopaedic surgery in the United States and beyond through the American Orthopaedic Association’s (AOA) North American Traveling Fellowship and American-British-Canadian Traveling Fellowship. He mentored at least 10 faculty members in obtaining similar fellowships that have enhanced the prestige of orthopaedic surgery.

Dr. Zuckerman earned his medical degree from the Medical College of Wisconsin in Milwaukee. He completed a residency in orthopedic surgery at University of Washington Medical Center and a fellowship in reconstructive surgery at Brigham and Women’s Hospital in Boston.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”